Rheumatology
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
17 May, 2022 | 10:54h | UTC
Commentary on Twitter
Our 2022 EULAR points to consider on Therapeutic drug monitoring of biologics just published in @ARD_BMJ
A real pleasure being part of this steering group & collaborative taskforce expertly led by @ProfJohnIsaacs
Clear points for practice& research👇https://t.co/YesEjajaIK pic.twitter.com/cQw8o1bjUw
— Meghna Jani (@MeghnaJani) May 15, 2022
M-A: Worldwide incidence and prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis.
17 May, 2022 | 10:20h | UTC
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases.
16 May, 2022 | 02:11h | UTC
Commentary on Twitter
2022 #EULAR points to consider for remote care in #rheumatic and #musculoskeletal diseaseshttps://t.co/oB0Fo0wzoM pic.twitter.com/LS95rSvCmh
— Annals of the Rheumatic Diseases (@eular_ARD) April 27, 2022
Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy.
13 May, 2022 | 11:05h | UTC
Commentary on Twitter
NEW: Narrative review from @esteves_gp @eimeardol et al summarises evidence regarding #nutritional recommendations during GC therapy and highlights gaps in the literature.
✅ Targeted nutritional strategies may help alleviate adverse effects of GCs.📰 https://t.co/8NpIxkYmIv pic.twitter.com/RArjGTw6sA
— Rheumatology & Rheumatology Advances in Practice (@RheumJnl) April 22, 2022
Review: Vertebroplasty for osteoporotic vertebral fracture – Three among four double-blind studies which used a sham procedure did not confirm the benefit suggested by previous studies.
13 May, 2022 | 10:44h | UTCVertebroplasty for osteoporotic vertebral fracture – RMD Open
Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica reduces flares in a protocol of rapid glucocorticoid tapering (from 20 mg to 0 mg over 11 weeks).
13 May, 2022 | 10:42h | UTCTocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Systematic Review: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
11 May, 2022 | 11:04h | UTC
Phase 2 RCT: Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease.
9 May, 2022 | 01:38h | UTCNews Release: Breakthrough in treatment for Dupuytren’s disease – University of Oxford
Commentary: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian
Commentary on Twitter
NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4
— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.
5 May, 2022 | 10:22h | UTC
Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica.
4 May, 2022 | 08:04h | UTCTocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary on Twitter
A 24 week RCT in patients with new-onset #PMR evaluating tocilizumab vs. placebo:
▶️ Primary Outcome: 63.2% of Toci vs. 11.8% in the PLC group reached glucocorticoid free remission at week 16
▶️ time to relapse: 130 days in Toci vs 82d in PLC grouphttps://t.co/4ylx2CqebR— Annals of the Rheumatic Diseases (@eular_ARD) February 28, 2022
Phase 2 RCT: Efficacy and safety of Deucravacitinib, a selective TYK2 inhibitor, in psoriatic arthritis.
4 May, 2022 | 08:09h | UTC
Commentary on Twitter
https://twitter.com/ARD_BMJ/status/1499542657693097985
Phase 2 RCT: Efficacy and safety of mavrilimumab in giant cell arteritis.
4 May, 2022 | 08:07h | UTC
Commentary on Twitter
New phase II trial data 📈 for #giantcellarteriitis: Mavrilimumab, an anti-GM-CSF antibody, showed:
✅ longer time to flare
✅ higher rate of sustained remission
❎ similar rate of adverse events compared to placebohttps://t.co/2MDLch2Zmg pic.twitter.com/Rl1AgamQKG— Annals of the Rheumatic Diseases (@eular_ARD) March 10, 2022
M-A: Adverse events relating to prolonged hard collar immobilization.
3 May, 2022 | 10:27h | UTC
Checkpoint inhibitor–associated arthritis: a systematic review of case reports and case series.
28 Apr, 2022 | 07:58h | UTC
Gout in the ED: Pearls and pitfalls.
26 Apr, 2022 | 07:37h | UTCGout in the ED: Pearls and Pitfalls – emDocs
Review: The challenges in the primary prevention of osteoarthritis.
26 Apr, 2022 | 07:29h | UTCThe Challenges in the Primary Prevention of Osteoarthritis – Clinics in Geriatric Medicine
Commentary on Twitter
The Challenges in the Primary Prevention of Osteoarthritis
Opportunities for preventing OA across the lifespan.
👀👀👇👇https://t.co/9mdvpeoEW9 pic.twitter.com/VexC3qEOlr
— Physio Meets Science (@PhysioMeScience) April 18, 2022
Under a (CC BY 4.0) license
RCT: Subacromial balloon spacer is not better than debridement only for irreparable rotator cuff tears of the shoulder.
25 Apr, 2022 | 00:27h | UTC
RCT: Allopurinol is noninferior to febuxostat for controlling gout flares.
19 Apr, 2022 | 02:05h | UTCComparative Effectiveness of Allopurinol and Febuxostat in Gout Management – NEJM Evidence (link to abstract – $ for full-text)
Review: Paradoxical reactions to biologicals in chronic inflammatory systemic diseases.
19 Apr, 2022 | 01:48h | UTC
Review: The safety of antirheumatic drugs.
19 Apr, 2022 | 01:42h | UTCThe Safety of Antirheumatic Drugs – Deutsches Ärzteblatt International
Cohort Study: Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer.
14 Apr, 2022 | 07:59h | UTCCommentary: Men treated for prostate cancer have increased fracture risk, yet few complete DXA screening – HealthImaging
Commentary on Twitter
In this cohort study, osteoporosis screening rates for over 50,000 elderly men with prostate cancer receiving hormonal therapy nationwide were very low; men who were screened were less likely to suffer major fractures in follow-up. https://t.co/RMz1bvEgiA
— JAMA Network Open (@JAMANetworkOpen) April 1, 2022
Acute phase of Kawasaki disease: a review of national guideline recommendations.
12 Apr, 2022 | 08:32h | UTC
UK clinical guideline for the prevention and treatment of osteoporosis.
11 Apr, 2022 | 01:33h | UTCUK clinical guideline for the prevention and treatment of osteoporosis – Archives of Osteoporosis
RCT: Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anesthetic injection for hip osteoarthritis.
7 Apr, 2022 | 08:37h | UTCNews Release: Steroid injections may provide longer lasting benefits for hip pain than current best care – BMJ
Commentary on Twitter
Adding an ultrasound guided corticosteroid and local anaesthetic injection to advice and education offers rapid and sustained improvements in pain and function, finds new research https://t.co/fQHzvKv2wL
— The BMJ (@bmj_latest) April 7, 2022
RCT: Effect of intramuscular vs. intra-articular glucocorticoid injection on pain among adults with knee osteoarthritis.
7 Apr, 2022 | 08:35h | UTC
Commentary on Twitter
This RCT found IM steroid injections were inferior to intrarticular injections for reducing pain in patients with knee osteoarthritis at 4 weeks but were noninferior at 8 and 24 weeks after injection. https://t.co/opq1C2BP8c pic.twitter.com/ucx4lvRDJQ
— JAMA Network Open (@JAMANetworkOpen) April 5, 2022